1. Damman K, Testani JM. The kidney in heart failure: an update.
Eur Heart J 2015;36:1437–1444.
2. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management.
Nat Rev Nephrol 2013;9:99–111.
3. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.
J Am Coll Cardiol 2009;53:589–596.
4. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease.
J Am Coll Cardiol 2009;53:582–588.
5. Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M. Focus on renal congestion in heart failure.
Clin Kidney J 2016;9:39–47.
6. Di Nicolò P. The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure.
Heart Fail Rev 2018;23:291–302.
8. Källskog O, Lindbrom LO, Ulfendahl HR, Wolgast M. Hydrostatic pressures within the vascular structures of the rat kidney.
Pflugers Arch 1976;363:205–210.
9. Willassen Y, Ofstad J. Postglomerular vascular hydrostatic and oncotic pressures during acute saline volume expansion in normotensive man.
Scand J Clin Lab Invest 1979;39:707–715.
10. Willassen Y, Ofstad J. Intrarenal venous and cortical catheter pressures in the dog kidney.
Scand J Clin Lab Invest 1979;39:697–705.
11. Lemley KV, Kriz W. Structure and function of the renal vasculature. In: Tisher CC, Brenner BM, Renal pathology. 2nd ed. J.B. Lippincott Company; 1994. p. 981–1026.
12. Zou AP, Cowley AW Jr. Reactive oxygen species and molecular regulation of renal oxygenation.
Acta Physiol Scand 2003;179:233–241.
13. Cowley AW Jr. Role of the renal medulla in volume and arterial pressure regulation.
Am J Physiol 1997;273:R1–R15.
14. Mori T, Hirose T, Kinugasa S. Treatment of renal congestion by tolvaptan.
Hypertens Res 2019;42:745–748.
15. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis.
Clin J Am Soc Nephrol 2013;8:1482–1493.
16. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem?
Crit Care Med 2008;36:S146–S151.
18. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome.
J Am Coll Cardiol 2008;52:1527–1539.
19. Novikov IuV, Shormanov IS. Renal vascular system in right heart overload with varying circulatory compensation.
Angiol Sosud Khir 2006;12:13–19.
20. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure: relationship of cardiac index to kidney function.
Drugs 1990;39 Suppl 4:10–24.
21. Hall JE. Chapter 26. Urine formation by the kidneys: I. Glomerular filtration, renal blood flow, and their control. In: Hall JE, Guyton and Hall textbook of medical physiology. 12th ed. Saunders; 2010. p. 303–322.
22. Abuelo JG. Normotensive ischemic acute renal failure.
N Engl J Med 2007;357:797–805.
23. Langenberg C, Bagshaw SM, May CN, Bellomo R. The histopathology of septic acute kidney injury: a systematic review.
Crit Care 2008;12:R38.
24. Bellomo R, Wan L, Langenberg C, May C. Septic acute kidney injury: new concepts.
Nephron Exp Nephrol 2008;109:e95–e100.
25. Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: expert opinion of the Working Group for Nephrology, ESICM.
Intensive Care Med 2010;36:392–411.
26. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med 2001;345:1368–1377.
27. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Crit Care Med 2004;32:858–873.
28. Levy MM, Pronovost PJ, Dellinger RP, et al. Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome.
Crit Care Med 2004;32:S595–S597.
29. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock.
N Engl J Med 2014;370:1583–1593.
30. Wencker D. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure.
Curr Heart Fail Rep 2007;4:134–138.
31. Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man.
J Clin Invest 1947;26:1010–1022.
32. Mori T, Ohsaki Y, Oba-Yabana I, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure.
Hepatol Res 2017;47:11–22.
33. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. Fluid balance and acute kidney injury.
Nat Rev Nephrol 2010;6:107–115.
34. Doty JM, Saggi BH, Blocher CR, et al. Effects of increased renal parenchymal pressure on renal function.
J Trauma 2000;48:874–877.
35. Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestion but not low output.
Clin Cardiol 2011;34:113–116.
36. Legrand M, Dupuis C, Simon C, et al. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study.
Crit Care 2013;17:R278.
37. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.
JAMA 2005;294:1625–1633.
38. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial.
J Am Coll Cardiol 2008;51:1268–1274.
39. Hanberg JS, Sury K, Wilson FP, et al. Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure.
J Am Coll Cardiol 2016;67:2199–2208.
40. Al-Kindi SG, Oliveira GH. Lack of association between cardiac index and kidney dysfunction: validation in patients awaiting heart transplantation.
J Am Coll Cardiol 2016;68:876–877.
41. Hemmi S, Matsumoto N, Jike T, et al. Proximal tubule morphology in rats with renal congestion: a study involving the in vivo cryotechnique.
Med Mol Morphol 2015;48:92–103.
42. Morsing P, Stenberg A, Müller-Suur C, Persson AE. Tubuloglomerular feedback in animals with unilateral, partial ureteral occlusion.
Kidney Int 1987;32:212–218.
43. Jin C, Hu C, Polichnowski A, et al. Effects of renal perfusion pressure on renal medullary hydrogen peroxide and nitric oxide production.
Hypertension 2009;53:1048–1053.
44. Mori T, Polichnowski A, Glocka P, et al. High perfusion pressure accelerates renal injury in salt-sensitive hypertension.
J Am Soc Nephrol 2008;19:1472–1482.
45. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition.
J Clin Invest 2007;117:3810–3820.
47. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure.
N Engl J Med 1999;341:577–585.
48. Blankstein R, Bakris GL. Renal hemodynamic changes in heart failure.
Heart Fail Clin 2008;4:411–423.
49. Ruggenenti P, Remuzzi G. Worsening kidney function in decompensated heart failure: treat the heart, don’t mind the kidney.
Eur Heart J 2011;32:2476–2478.
50. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?
J Am Coll Cardiol 2006;47:1–8.
51. Guazzi M, Gatto P, Giusti G, et al. Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction.
Int J Cardiol 2013;169:379–384.
52. Ross EA. Congestive renal failure: the pathophysiology and treatment of renal venous hypertension.
J Card Fail 2012;18:930–938.
53. Colombo PC, Ganda A, Lin J, et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome.
Heart Fail Rev 2012;17:177–190.
54. Colombo PC, Onat D, Harxhi A, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation.
Eur Heart J 2014;35:448–454.
55. Cheatham ML, White MW, Sagraves SG, Johnson JL, Block EF. Abdominal perfusion pressure: a superior parameter in the assessment of intra-abdominal hypertension.
J Trauma 2000;49:621–627.
56. Bloomfield GL, Blocher CR, Fakhry IF, Sica DA, Sugerman HJ. Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels.
J Trauma 1997;42:997–1005.
57. Harman PK, Kron IL, McLachlan HD, Freedlender AE, Nolan SP. Elevated intra-abdominal pressure and renal function.
Ann Surg 1982;196:594–597.
58. Karayannis G, Triposkiadis F, Skoularigis J, Georgoulias P, Butler J, Giamouzis G. The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.
Curr Heart Fail Rep 2013;10:441–449.
59. Mebazaa A. Congestion and cardiorenal syndromes.
Contrib Nephrol 2010;165:140–144.
60. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice.
Eur J Heart Fail 2008;10:824–839.
61. Pfister R, Müller-Ehmsen J, Hagemeister J, Hellmich M, Erdmann E, Schneider CA. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure.
Intern Med J 2011;41:467–472.
62. Iida N, Seo Y, Sai S, et al. Clinical implications of intrarenal hemodynamic evaluation by Doppler ultrasonography in heart failure.
JACC Heart Fail 2016;4:674–682.
63. Seo Y, Iida N, Yamamoto M, Ishizu T, Ieda M, Ohte N. Doppler-derived intrarenal venous flow mirrors right-sided heart hemodynamics in patients with cardiovascular disease.
Circ J 2020;84:1552–1559.
64. Komuro K, Seo Y, Yamamoto M, et al. Assessment of renal perfusion impairment in a rat model of acute renal congestion using contrast-enhanced ultrasonography.
Heart Vessels 2018;33:434–440.
65. Michael Felker G. Diuretic management in heart failure.
Congest Heart Fail 2010;16 Suppl 1:S68–S72.
66. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial.
Eur J Heart Fail 2007;9:1064–1069.
67. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).
J Am Coll Cardiol 2003;42:705–708.
68. Leto L, Aspromonte N, Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review.
Heart Fail Rev 2014;19:237–246.
69. Schrier RW. Use of diuretics in heart failure and cirrhosis.
Semin Nephrol 2011;31:503–512.
70. Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B. Everything we always wanted to know about furosemide but were afraid to ask.
Am J Physiol Renal Physiol 2016;310:F958–F971.
71. Braam B, Mitchell KD, Fox J, Navar LG. Proximal tubular secretion of angiotensin II in rats.
Am J Physiol 1993;264:F891–F898.
72. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat.
J Clin Invest 1990;86:1352–1357.
73. Petersen JS, DiBona GF. Furosemide elicits immediate sympathoexcitation via a renal mechanism independent of angiotensin II.
Pharmacol Toxicol 1995;77:106–113.
74. Petersen JS, DiBona GF. Reflex control of renal sympathetic nerve activity during furosemide diuresis in rats.
Am J Physiol 1994;266:R537–R545.
75. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure.
N Engl J Med 2011;364:797–805.
76. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
Circulation 2000;102:203–210.
77. Mehta RL, Pascual MT, Soroko S, Chertow GM; PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure.
JAMA 2002;288:2547–2553.
78. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Am J Physiol Renal Physiol 2006;290:F273–F278.
79. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure.
BMJ 2006;333:420.
80. Hanberg JS, Tang WH, Wilson FP, et al. An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial.
Int J Cardiol 2017;241:277–282.
81. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Cardiovasc Drugs Ther 2011;25 Suppl 1:S33–S45.
82. Chiba H, Seo Y, Sai S, Namekawa M, Ishizu T, Aonuma K. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion.
Hypertens Res 2019;42:319–328.
83. Morooka H, Iwanaga Y, Tamaki Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Circ Heart Fail 2012;5:484–492.
84. Mori T, Oba I, Koizumi K, et al. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
Adv Perit Dial 2013;29:33–37.
85. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Circulation 2003;107:2690–2696.
86. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans.
Lancet 2008;371:1624–1632.
87. Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure.
J Am Coll Cardiol 2017;69:1399–1406.
88. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
J Cardiol 2013;61:169–174.
89. Tamaki S, Sato Y, Yamada T, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction: prospective randomized controlled study.
Circ J 2017;81:740–747.
93. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
JAMA 2007;297:1332–1343.
94. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
JAMA 2004;291:1963–1971.
95. Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: results from the K-STAR Study.
Circ J 2017;82:159–167.
96. Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T Trial.
JACC Heart Fail 2020;8:157–168.
97. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.
Am Heart J 2004;147:331–338.
98. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.
Circulation 2009;119:1977–2016.
99. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Eur Heart J 2008;29:2388–2442.
100. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.
J Am Coll Cardiol 2007;49:675–683.
101. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome.
N Engl J Med 2012;367:2296–2304.
102. Marenzi G, Muratori M, Cosentino ER, et al. Continuous ultrafiltration for congestive heart failure: the CUORE trial.
J Card Fail 2014;20:9–17.
103. Arimura T, Abe M, Shiga H, Katayama H, Kaizu K, Oda S. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013.
J Artif Organs 2017;20:244–251.
105. Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Dialyzer classification and mortality in hemodialysis patients: a 3-year nationwide cohort study.
Front Med (Lausanne) 2021;8:740461.